Innovent unveiled new findings from its Phase 1 trial of the novel anti-CLDN18.2 ADC (IBI343) for advanced pancreatic cancer at the ESMO Asia Congress 2024.

Merck's experimental drug Zilovertamab Vedotin combined with R-CHP achieved a complete response rate of 100% at a dosage of 1.75 mg/kg.

PureTech showcases LYT-200 (anti-galectin-9 monoclonal antibody) data for relapsed/refractory AML/MDS at the 2024 ASH Annual Meeting.

Galapagos Reveals Promising New Findings from Ongoing Phase 1/2 Trial of CD19 CAR T-Cell Treatment, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma.

The clinical trial of Epcoritamab (DuoBody® CD3xCD20) combination therapy demonstrates significant response rates in patients with relapsed or refractory follicular lymphoma (FL).

WaveBreak reveals initial preclinical results showing that the small molecule WTX-245 effectively inhibits the underlying causes of TDP-43 pathology.

Beacon Therapeutics Shares Positive Three-Month Results from Phase 2 DAWN Study of laru-zova (AGTC-501) for X-Linked Retinitis Pigmentosa (XLRP) Patients.

IMFINZI® (durvalumab) receives Priority Review status in the US for those with muscle-invasive bladder cancer.

Shanghai Henlius Biotech, has reported that the NMPA has accepted the NDA for its proprietary pertuzumab biosimilar HLX11.

Currently, only three CXCR4 (C-X-C motif chemokine receptor 4) antagonists have been approved globally: Plerixafor, Motixafortide, and Mavorixafor.

Henlius has obtained IND approval from NMPA for a Phase 1b/2 clinical study of its new PD-L1-targeting ADC, HLX43.

Nkarta announces approval for investigator-led study in Myasthenia Gravis and begins enrollment for Ntrust-2.